Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 5OTHER 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Gynecologic 2Thoracic 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 150Stomach Neoplasms 52Neoplasms 49Pancreatic Neoplasms 41Neoplasm Metastasis 32Squamous Cell Carcinoma of Head and Neck 26Head and Neck Neoplasms 25Esophageal Neoplasms 24Colonic Neoplasms 22Rectal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Esophageal Squamous Cell Carcinoma 15Adenocarcinoma 14Adenocarcinoma Of Esophagus 12Cholangiocarcinoma 11Biliary Tract Neoplasms 11Ovarian Neoplasms 9Triple Negative Breast Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Urinary Bladder Neoplasms 6Sarcoma 6Keratosis, Actinic 6Gastrointestinal Neoplasms 6Endometrial Neoplasms 6Carcinoma, Squamous Cell 6Advanced Solid Tumors 6

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × Fluorouracil × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Novartis

Phase 1 Completed
167 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡